ReviewEuropean urology open science2025
Clinical and Molecular Predictors of Response and Survival in Patients with Urothelial Carcinoma Treated with Enfortumab Vedotin: A Systematic Review and Meta-analysis.
Review in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Enfortumab vedotin (EV) is emerging as a standard of care for advanced urothelial carcinoma (UC), but identification of which patients might benefit the most or least remains an unmet need. Our aim was to identify clinical and molecular parameters associated with EV sensitivity in patients with advanced UC after failure of previous platinum and immune checkpoint inhibitor (ICI) therapy. Methods: We queried the PubMed, Embase, and Cochrane Library databases up to January 2024. The review protocol was registered on PROSPERO (CRD42023484339). The outcome measures were the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS). Key findings and limitations: A total of 23 studies were included. Analyses for 1340 patients revealed a cumulative ORR of 48%, with higher rates in real-world studies (51%) than in clinical trials (44%). EV was similarly effective in bladder and upper-tract UC in terms of OS and PFS, but the ORR was slightly higher in upper-tract UC (odds ratio [OR] 1.29, 95% confidence interval [CI] 1.01-1.63; Conclusions and clinical implications: EV is an effective therapy in advanced UC. The predictive parameters identified in our analyses, such as ECOG performance status, Bellmunt score, non-UC histology, and response to prior ICI and platinum treatment, can be used to guide optimal patient selection for EV or alternative therapies. Patient summary: We summarize data from published studies to identify factors that influence outcomes for patients with advanced cancer of the urinary tract treated with a drug called enfortumab vedotin. An understanding of these factors can help in personalizing therapy for patients and improving their care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.